Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE

• DOI: 10.1016/j.rmed.2023.107285
• Publication Date: 2023-06-07T18:09:49Z
• Authors: Reynold A. Panett...; Njira Lugogo; Wendy C. Moore; Bradley E. Chipps; Brett Jepson; Wenjiong Zhou; Christopher S. Am...; Eduardo Genofre; Donna D. Carstens
• Keywords: Adult; Eosinophils; Double-Blind Method; Adrenal Cortex Hormones; Disease Progression; Humans; Anti-Asthmatic Agents; Pulmonary Eosinophilia; Asthma; 3. Good health

Patients with eosinophilic severe asthma (SA) have an increased risk of asthma exacerbations. Benralizumab is approved for eosinophilic SA, and there is great value in understanding real-world effectiveness.The aim of this analysis was to examine the effectiveness of benralizumab in a real-world cohort of subspecialist-treated US patients with eosinophilic SA.CHRONICLE is an ongoing, noninterventional study of subspecialist-treated US adults with SA receiving biologics, maintenance systemic corticosteroids, or those persistently uncontrolled by high-dose inhaled corticosteroids with additional controllers. For this analysis, eligible patients enrolled from February 2018 to February 2021, had received ≥ 1 dose of benralizumab, and had study data for ≥ 3 months before and after benralizumab initiation. The primary analysis included patients with prior exacerbations reported and 12 months of outcomes data before and after initiation. Patient outcomes occurring 6-12 months before and after initiation were also evaluated.A total of 317 patients had ≥ 3 months of follow-up before and after first benralizumab dose. For patients with 12 months (n = 107) and 6-12 months (n = 166) of data, significant reductions were observed in annualized rates of exacerbations (62%; P < 0.001 and 65%; P < 0.001, respectively), with similar reductions in the rates of hospitalizations and emergency department visits. Benralizumab recipients with blood eosinophil counts (BEC) of ≥ 300/ μL and < 300/ μL at baseline and 12 months of data also had significant reductions in exacerbations (68%; P < 0.001, 61%; P < 0.001).This real-world, noninterventional analysis reinforces the clinical value of benralizumab in the management of patients with eosinophilic SA.